Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 51.71
- Piotroski Score 3.00
- Grade Buy
- Symbol (NMRA)
- Company Neumora Therapeutics, Inc. Common Stock
- Price $13.41
- Changes Percentage (-0.67%)
- Change -$0.09
- Day Low $12.80
- Day High $13.44
- Year High $21.00
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $24.50
- High Stock Price Target $29.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.59
- Trailing P/E Ratio -6.26
- Forward P/E Ratio -6.26
- P/E Growth -6.26
- Net Income $-235,925,000
Income Statement
Quarterly
Annual
Latest News of NMRA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Neumora Therapeutics (NASDAQ:NMRA) Is In A Good Position To Deliver On Growth Plans
Despite being unprofitable, companies like Neumora Therapeutics (NASDAQ:NMRA) can still be attractive to shareholders if they have a good business model at the right price....
By Yahoo! Finance | 1 day ago
